Related by context. All words. (Click for frequent words.) 83 placebo p = 73 statistically significant p 71 statistically significant p = 70 p = #.# [002] 70 P = .# 70 p = #.# [004] 69 tolterodine ER 69 achieved statistical significance 69 achieved ACR# 69 placebo 68 MADRS score 68 CI -#.# 68 oxycodone CR 68 p = 67 mg QD 67 -#.# mg dL [002] 67 P ≤ 67 -#.# mg dL [001] 67 #.#/#.# mmHg [001] 67 mcg BID 67 lopinavir r arm 67 lispro 66 lumbar spine BMD 66 plus methotrexate 66 mg TID 66 ACR# response 66 mg ustekinumab 65 lopinavir r 65 racemic albuterol 65 Xalatan R 65 NPH insulin 65 4mg/kg 65 baseline HbA1c 65 log# 65 8mg/kg 65 mcg QD 65 p = NS 65 Psoriasis Area 65 p = .# [002] 65 mg p = 65 plus MTX 64 sUA 64 log# IU mL 64 statistical significance p 64 CIMZIA TM 64 Montgomery Asberg Depression 64 clodronate 64 budesonide pMDI 64 chlorambucil 64 TAXUS p value 64 linaclotide treated 64 insulin detemir 64 mcg Albuferon 64 fluticasone salmeterol 64 #mg/day [002] 64 titrated glipizide 64 #mg BID [001] 63 tirofiban 63 infliximab monotherapy 63 mEq L 63 certolizumab 63 methotrexate monotherapy 63 #mg/day [001] 63 IOP lowering 63 Secondary endpoints included 63 HDRS 63 x ULN 63 % Confidence Interval 63 mg kg dose 63 ropivacaine 63 annualized relapse 63 binary restenosis 63 HBeAg seroconversion 63 Rating Scale MADRS 63 #.#mg/dL 63 FOLFOX4 63 receiving ISENTRESS 63 mcg mL 63 tiotropium 63 Cmax 62 #mg BID [003] 62 achieved PASI 62 HAQ DI 62 confidence interval CI 62 quetiapine 62 5-FU/LV 62 nmol liter 62 mmHg p = 62 serum urate 62 urate lowering therapy 62 AUA Symptom Score 62 #mg doses [002] 62 mg d 62 log# reduction 62 unfractionated heparin 62 reinfarction 62 nicardipine 62 tipranavir r 62 severe hypoglycemic 62 adjunctive placebo 62 glimepiride 62 tapentadol ER 62 FOLFOX4 alone 62 mg BID 62 plus dexamethasone 61 CDAI score 61 -#.# ± [002] 61 ADAS cog 61 plus glimepiride 61 mcg kg 61 CI #.#-#.# [002] 61 log# copies mL 61 creatinine ratio 61 Crohn Disease Activity 61 mg dose 61 oxycodone IR 61 % CI #.#-#.# [001] 61 octreotide LAR 61 desvenlafaxine succinate 61 laboratory abnormalities 61 mmol l 61 dapagliflozin plus 61 HbA 1c 61 Pred Forte 61 MADRS 61 HBeAg negative patients 61 demonstrated statistically significant 61 abdominal pain abdominal discomfort 61 peginterferon alfa 2a 61 mcg albinterferon alfa 2b 61 % CI #.#-#.# [003] 61 sham injections 61 3mg/kg 61 oral allopurinol 61 morphometric vertebral fractures 61 mg simvastatin 61 ALVESCO 61 RLAI 61 saline placebo 61 aspartate aminotransferase 61 HbA 1c levels 61 confidence interval #.#-#.# 61 secondary endpoint 61 nadolol 61 mg kg belimumab 60 PSA nadir 60 mg qd 60 Lucentis monotherapy 60 ATACAND 60 #mg QD [001] 60 IPSS 60 #.#/#.# mm Hg [003] 60 biphasic insulin aspart 60 Hazard Ratio HR 60 definite stent thrombosis 60 incontinence episodes 60 CCyR 60 LEXIVA r 60 μmol L 60 serum phosphorus 60 rosuvastatin #mg 60 trough FEV1 60 solifenacin 60 discontinuations due 60 TEAEs 60 transaminase elevations 60 glycated hemoglobin levels 60 sumatriptan naproxen sodium 60 pg ml 60 mmol L 60 YMRS 60 CR nPR 60 splenectomized patients 60 #mg/kg [002] 60 REYATAZ r arm 60 SELENA SLEDAI score 60 tolvaptan 60 gastric pH 60 statistically significant reduction 60 endometrial thickness 60 adjunctive ABILIFY 60 APTIVUS r 60 ACTEMRA TM 60 baseline A1C 60 LVEF 60 mg kg 60 nonsignificant difference 60 PANSS total 60 IELT 60 bosentan 60 QTcF 60 receiving VICTRELIS 60 Q2W 60 PREZISTA ritonavir 60 seropositive patients 60 adalimumab 60 T2 lesion volume 60 serologically active patients 60 fasting plasma glucose FPG 60 placebo dexamethasone 60 #μg [002] 59 ACR# responses 59 mg + GLY 59 % CI #.#-#.# [006] 59 alanine aminotransferase ALT 59 IU mL 59 CSBMs 59 ULORIC 59 insulin glargine 59 subcutaneous insulin 59 Ishak fibrosis score 59 virologic response 59 HbA1c levels 59 ritonavir boosted 59 HAM D# 59 abacavir lamivudine 59 PANSS scores 59 lumbar spine bone 59 PASI scores 59 retinal thickness 59 -#.# log# copies mL 59 hypoglycemic events 59 pmol L 59 median PFS 59 eplerenone 59 pCR 59 highly emetogenic 59 hypokalemia 59 mg tid 59 p ≤ 59 Montgomery Åsberg Depression 59 alanine aminotransferase 59 mg kg Hematide 59 DAS# [002] 59 interquartile range 59 GERD symptom 59 % CI #.#-#.# [002] 59 nondiabetic patients 59 statistically significant improvement 59 comparator arm 59 placebo fluoxetine 59 abciximab 59 #mg dose [003] 59 mg Lucentis 59 International Prostate Symptom 59 HAM D# scores 59 + TZD 59 nocturnal awakenings 59 spontaneous bowel movements 59 plus medroxyprogesterone acetate 59 timepoint 59 nonfatal MI 59 mesalamine granules 59 μg kg 59 zonisamide SR 59 WOMAC pain 59 Doxil ® 59 ketorolac 59 dyspnea 59 febrile neutropenia 59 symptom severity 59 DAS# remission 59 biochemical relapse 59 q#h 59 rimonabant #mg 59 liver histology 59 μg mL 59 mL/min/#.# m 2 59 TAXUS Express Stent 59 FEV1 59 IBDQ 59 sirolimus eluting stent 59 mg dL 59 % CI #.#-#.# [007] 59 esomeprazole 59 peripheral edema 59 refractory ischemia 58 adefovir 58 AUC0 58 atorvastatin #mg 58 clinically meaningful improvement 58 systemic embolism 58 rimonabant #mg/day 58 splenectomized 58 XIENCE V vs. 58 low dose Iluvien 58 ng dL 58 irbesartan 58 primary efficacy endpoint 58 detemir 58 plasma leptin 58 oral diclofenac 58 undetectable HBV DNA 58 peginterferon alfa 2b 58 Taxus Stent 58 mild renal insufficiency 58 postintervention 58 extrapyramidal symptoms 58 progression TTP 58 TMC# r 58 creatinine clearance 58 nasopharyngitis 58 Score DAS# 58 ACR# [002] 58 Index CDAI 58 unfractionated heparin UFH 58 Flu Cy 58 #mg QD [002] 58 #ug [001] 58 salmeterol fluticasone 58 PANSS 58 zolmitriptan 58 Zometa hazard 58 Secondary endpoints 58 plus GP IIb 58 elevated ALT 58 complete cytogenetic 58 ejection fractions 58 MoxDuo TM IR 58 IIIa inhibitors 58 OADs 58 leukocyte count 58 CNS LS 58 intramuscularly 58 apnea hypopnea index 58 certolizumab pegol 58 hip BMD 58 PREZISTA r arm 58 Secondary endpoints include 58 FOLFIRI alone 58 degarelix 58 systemic corticosteroid 58 XIENCE V PROMUS Stent 58 posttreatment 58 ARB telmisartan 58 analgesic efficacy 58 SGRQ 58 adriamycin 58 pramipexole 58 idraparinux 58 Negative Syndrome 58 Free Survival PFS 58 #.#-#.# p = 58 BMS p = 58 prespecified 58 tamsulosin 58 pooled comparator 58 copies mL 58 p = .# [001] 58 methacholine challenge 58 PEG Intron 58 nonsignificant 58 mcg dose 58 Lamictal XR 58 ALT normalization 58 attain statistical significance 58 mCi kg 58 SVR# 58 receiving golimumab 58 dalteparin 58 PRADAXA #mg 58 HOMA IR 58 ug kg 58 postdose 58 paricalcitol 58 tapentadol IR 58 mcg doses 58 + PH# 58 urge urinary incontinence 58 quetiapine XR 58 HbA1c 58 incidence ≥ 58 inactive placebo 58 MMSE score 58 LPV r 58 etanercept 58 treatment emergent adverse 57 ng dl 57 active comparator 57 ADCS CGIC 57 p = #.# [003] 57 nasal symptom 57 achieving PASI 57 moderate renal impairment 57 mitoxantrone 57 elevated creatinine 57 rizatriptan 57 sustained virologic response 57 plasma HCV RNA 57 interferon alfa 2b 57 μg 57 â ‰ ¥ 57 sd = 57 prednisone prednisolone plus 57 CI = 57 #Gy 57 TLUS 57 serum potassium 57 Alzheimer Disease Assessment 57 -#.# p = 57 timepoints 57 insulin lispro 57 DAS# scores 57 Hazard Ratio = 57 recurrent venous thromboembolism 57 nonresponders 57 SSRI SNRI 57 ALND 57 CrCl 57 NIH CPSI 57 Peg IFN 57 Pegasys ® 57 FluCAM 57 alteplase 57 sustained virological response 57 g dL 57 Lupuzor ™ 57 mcg kg min 57 HBeAg 57 severe neutropenia 57 fasting plasma glucose 57 FOLFIRI 57 aminotransferase elevations greater 57 serum HBV DNA 57 HbA1C levels 57 pg mL 57 GP IIb IIIa inhibitors 57 CR CRu 57 bronchodilation 57 ABC/3TC 57 doxazosin 57 IM progesterone 57 SGPT 57 periprocedural 57 headache nasopharyngitis 57 avosentan 57 lamivudine monotherapy 57 recurrent ischemia 57 mean baseline HbA1c 57 Acetate Rectal Suppositories 57 dyspareunia 57 BARACLUDE r 57 mg subcutaneous 57 CIMZIA ™ 57 Expanded Disability Status 57 quetiapine risperidone 57 nmol L 57 Hazard Ratio 57 enoxaparin 57 MACCE 57 IIIa inhibitor 57 sinus rhythm 57 LANTUS R 57 dose cytarabine 57 AUCs 57 fluticasone 57 CIMZIA TM certolizumab pegol 57 hypomagnesemia 57 amoxicillin clavulanate 57 risedronate 57 TNSS 57 QD dosing 57 lamotrigine 57 mg subcutaneously 57 FOLFOX 57 ipsilateral stroke 57 Scale cognitive subscale 57 piperacillin tazobactam 57 carboplatin paclitaxel 57 sUA levels 57 HIV RNA 57 mL kg 57 ug ml 57 alfa 2a 57 secondary endpoints 57 mg doses 56 left ventricular systolic 56 primary endpoint 56 adverse reactions incidence 56 ezetimibe simvastatin 56 lipid parameters 56 uM 56 adefovir treated 56 plus prednisone 56 inflammatory lesions 56 mmHg diastolic 56 severe exacerbations 56 atazanavir ritonavir 56 salmeterol HFA MDI 56 CsA 56 azathioprine 56 leukopenia 56 Visual Analogue Scale VAS 56 EBRT 56 STELARA ® 56 ibandronate 56 timolol 56 Thal Dex 56 nadroparin 56 mcg kg REBETOL 56 subcutaneous enoxaparin 56 anemia hemoglobin 56 Viread Emtriva Sustiva 56 tiotropium bromide 56 dose dependently 56 somatostatin analog 56 mRS 56 diameter stenosis 56 mitoxantrone plus 56 DAPT 56 IFN alfa 56 locoregional recurrence 56 thromboembolic events 56 NATRECOR R 56 concomitant medications 56 phonophobia 56 min -1 56 glycated hemoglobin HbA1c 56 Score IPSS 56 postmenopausal osteoporotic women 56 PROCTOCORT ® Suppository Hydrocortisone 56 BPH Symptom Score 56 ng mL 56 Scale EDSS 56 Engerix B 56 molindone 56 receiving VELCADE 56 interferon alfa 2a 56 pioglitazone 56 serum ALT 56 eszopiclone 56 clinically meaningful improvements 56 achieved mucosal healing 56 Index CDAI score 56 glargine 56 dacarbazine 56 generalized edema 56 CDAI 56 tolterodine 56 μg dose 56 intravitreal injections 56 salmeterol fluticasone propionate 56 corticosteroid dose 56 CK MB 56 IFN α 56 colesevelam HCl 56 TDF FTC 56 ACR Pedi 56 5FU 56 ACE inhibitor ramipril 56 serum phosphorous 56 Knodell necroinflammatory score 56 dose colchicine 56 achieved CCyR 56 urinary cortisol 56 mTSS 56 hemoglobin A1c HbA1c 56 SSRI citalopram 56 plus OBT 56 titrated glipizide plus 56 EC naproxen 56 dizziness nausea diarrhea 56 plus ribavirin 56 IRLS score 56 efavirenz EFV 56 1mg dose 56 Score TOS 56 UPDRS 56 cerebrovascular events 56 mm Hg 56 Target Lesion Revascularization TLR 56 pegylated interferon alfa 2b 56 dosing frequency 56 peak plasma concentrations 56 #.#g/day 56 ADHD Rating Scale 56 headache somnolence 56 urinary N telopeptide 56 Vancocin p = 56 NIHSS 56 nocturnal hypoglycaemia 56 secondary efficacy endpoint 56 atheroma volume 56 -#.# log# 56 ADAS Cog 56 neostigmine 56 micrograms mL 56 peginterferon alfa 2a #KD 56 isoproterenol 56 gout flares 56 elevated transaminases 56 noninferiority 56 chlorthalidone 56 REMICADE monotherapy 56 mg m² 56 mg/# hours 56 FOLFOX6 56 CorVue ™ 56 SBMs 56 #mg dose [001] 56 olanzapine 56 recurrent VTE 56 statistically significant 56 ribavirin RBV 56 complete cytogenetic response 56 tranylcypromine 56 CANCIDAS 56 cilostazol 56 diuretic chlorthalidone 56 fasting triglyceride levels 56 glulisine 56 endoscopic remission 56 HBeAg positive patients 56 LEXIVA 56 paresthesias 56 scores TNSS 56 detectable HCV RNA 56 ug dose 56 NNT = 56 neurologic progression 56 Baseline characteristics 55 weekly intravenous infusions 55 #.#mmol L [002] 55 achieve statistical significance 55 primary hypercholesterolemia 55 oral vancomycin 55 aPTT 55 oral olanzapine 55 PREMPRO 55 composite endpoint 55 mild renal impairment 55 Pain Intensity 55 bivalirudin 55 oral prednisone 55 transaminases 55 #mg/m# [001] 55 valsartan 55 aminotransferases 55 Navelbine 55 imipenem 55 lispro alone 55 postop 55 TPV r 55 dysuria 55 nausea photophobia 55 venlafaxine XR 55 receiving highly emetogenic 55 mmHg p 55 clinically meaningful reductions 55 RLS symptoms 55 neutrophil counts 55 g dl 55 nmol 55 LMWH 55 haloperidol 55 ARCOXIA 55 biologic DMARD 55 VAPRISOL 55 rotigotine 55 nM 55 plus prednisone prednisolone 55 gout flare 55 Brief Psychiatric 55 intima media thickness 55 mU L 55 virologic breakthrough 55 symptom exacerbation 55 IR prednisone 55 subcutaneous injections 55 virological response 55 serum IGF 55 cis retinoic acid 55 fibrinolysis 55 β blocker 55 Primary endpoints 55 primidone 55 everolimus eluting stents 55 oral antidiabetic medication 55 #mmHg [001] 55 Sustained virologic response 55 CI #.#-#.# [001] 55 WOMAC TM 55 aspartate aminotransferase AST 55 subcutaneously administered 55 HbA1C 55 NEVO ™ 55 acarbose 55 invasive carcinomas 55 -#.# mmol L 55 saline injections 55 VELCADE melphalan 55 LS BMD 55 daunorubicin 55 plasma folate 55 Inventory BPI 55 leuprorelin 55 interleukin IL -6 55 FUSILEV enhances 55 mL/min/#.# m2 55 #ng/ml 55 apolipoprotein B 55 pruritus 55 pegaptanib 55 prednisone prednisolone 55 infarct size 55 steroid dexamethasone 55 severe hypoglycemia 55 flutamide 55 DOXIL 55 methacholine 55 symptomatic VTE 55 hypogonadal 55 serum concentrations 55 MMSE scores 55 chloride secretion 55 hyperphenylalaninemia HPA due 55 ramipril 55 Stent thrombosis 55 Aptivus ® 55 Median survival 55 Elitek 55 fraction LVEF 55 pregabalin 55 zoledronate 55 prolonged QT interval 55 β blockers 55 non squamous histology 55 Median PFS 55 mU liter 55 fluticasone propionate 55 recurrent glioblastoma multiforme 55 metformin monotherapy 55 p = ns 55 angiographic restenosis 55 candesartan 55 PREZISTA r 55 beclomethasone dipropionate 55 ziprasidone 55 administered subcutaneously 55 IV bolus 55 response CCyR 55 MIRAPEX 55 EDSS score 55 H2RAs 55 bortezomib refractory 55 pentoxifylline 55 FOLPI 55 SBM frequency 55 oral rivaroxaban 55 mcg linaclotide 55 Scale PANSS 55 PaO 2 55 bezafibrate 55 mg eq 55 mg orally 55 dexmedetomidine 55 serum phosphate levels 55 virologic failure 55 oral levofloxacin 55 dobutamine 55 angiotensin converting enzyme inhibitors 55 belimumab 55 UPDRS motor 55 ≥ 55 serum phosphate 55 mIU L 55 hypercalcemia 55 euthyroid 55 dyspnoea 55 intravenous diuretics 55 #/#.# mcg 55 relapsed CLL 55 parkinsonian symptoms 55 clobazam 55 amprenavir 55 ALIMTA cisplatin 55 EpCAM expression 55 idarubicin 55 doxorubicin cyclophosphamide 55 platelet reactivity 55 FDA defined valvulopathy 55 serum uric acid 55 divalproex 55 candesartan cilexetil 55 experienced virologic failure 55 aspirin heparin 55 REYATAZ r 55 VIAject ® 55 tacrolimus ointment 55 A1c levels 55 acutely decompensated congestive heart 55 A1C levels 55 LAB GHRH 55 bleeding pallor 55 nighttime awakenings 55 #mg/m# [002] 55 corrected QT interval 55 achieved sustained virological 55 tipranavir ritonavir 55 caspofungin 55 luminal diameter 55 ecchymosis 55 TMP SMX 55 sotalol 55 hydroxymethyl coenzyme 55 dose dexamethasone 55 antihypertensive therapy 55 infliximab 55 arterial thromboembolic events 55 intravenous bolus 55 non menstrual pelvic 55 OAB symptoms 54 Y BOCS 54 ischemia driven 54 Hb A1C 54 paclitaxel eluting stents 54 Unified Parkinson Disease 54 seroprotection 54 ADCS ADL 54 tenofovir emtricitabine 54 oxcarbazepine 54 undetectable HCV RNA 54 mg kg ip 54 treprostinil 54 glycosylated hemoglobin 54 aspirin clopidogrel 54 metformin IR 54 glyburide 54 evaluable 54 #.#mmHg 54 non splenectomized 54 Cream USP 1 54 PegIFN RBV 54 nmol l 54 mm Hg systolic 54 partial remissions 54 postprandial glucose 54 thromboembolic 54 Non inferiority 54 #mg BID [002] 54 carotid IMT 54 balsalazide 54 microg 54 linezolid 54 highest tertile 54 rapid virologic response 54 hemoglobin A1c levels 54 malignancy HCM 54 bivalirudin monotherapy 54 serum testosterone 54 serum urate levels 54 glipizide 54 RGT arm 54 ticagrelor 54 mL sec 54 cGy 54 hematologic toxicity 54 preoperative PSA 54 mg/m2 dose 54 iodixanol 54 pulmonary exacerbation 54 pegylated interferon alfa 54 Adverse events 54 baseline Hb 54 UACR 54 lenalidomide dexamethasone 54 ‰ ¥ 54 rhGH 54 fluorouracil leucovorin 54 nodular partial response 54 secondary efficacy endpoints 54 MBq 54 placebo PBO 54 divalproex sodium 54 chemoradiation therapy 54 argatroban 54 ALT elevation 54 8mg 54 n = 54 ertapenem 54 microgram kg 54 aldosterone antagonist 54 XIENCE V demonstrated 54 lacosamide 54 nephrotoxicity 54 antibody titers 54 antipsychotic efficacy 54 AUA BPH Symptom Score 54 Stent p = 54 receiving APTIVUS r 54 neutrophil count 54 hypogonadal men 54 pyridostigmine 54 EUFLEXXA R 54 diastolic BP 54 Mg Uk 54 prolactin elevation 54 SUVmax 54 nmol L. 54 evaluable subjects 54 Scale EDSS score 54 knee osteoarthritis OA 54 prospectively stratified 54 Durezol 54 carvedilol 54 VIRAMUNE 54 somnolence dizziness 54 glycosylated hemoglobin HbA1c 54 lanthanum carbonate 54 potent CYP#A# inhibitors 54 Neuropsychiatric Inventory NPI 54 hemodynamically significant 54 inhaled fluticasone 54 NovoLog ® Mix 54 deep venous thromboses 54 radiographic progression 54 apremilast 54 urinary excretion 54 captopril 54 concomitant antibiotics 54 serum estradiol 54 nortriptyline 54 % CI #.#-#.# [004] 54 achieve sustained virologic 54 aprepitant 54 ventricular tachyarrhythmia 54 abdominal pain flatulence 54 corticosteroid therapy 54 events AEs 54 target lesion revascularization 54 VIIBRYD 54 thromboembolism 54 nevirapine Viramune 54 statin monotherapy 54 intact parathyroid hormone 54 unresectable HCC 54 Pharmacokinetics PK 54 Severity MSCS score 54 COZAAR 54 docetaxel prednisone 54 HCTZ 54 1mg 2mg 54 clomipramine 54 goserelin 54 deferoxamine 54 antiarrhythmic drug 54 albumin excretion rate 54 olmesartan 54 troponin T 54 HbA 1C 54 nonfatal myocardial infarction 54 fluticasone propionate FP 54 mg BID dose 54 serum triglyceride levels 54 cytogenetic response 54 fractional shortening 54 mg Androxal 54 GOUT 54 free survival PFS 54 logMAR 54 tobramycin inhalation solution 54 confirmed CCyR 54 docetaxel chemotherapy 54 briakinumab 54 Solid Tumors criteria 54 IRLS 54 lactate dehydrogenase 54 NYHA functional class 54 alfuzosin 54 oblimersen 54 pegylated liposomal doxorubicin 54 HCV RNA 54 receiving prophylactic anticoagulation 54 CC genotype 54 triamcinolone 54 ruboxistaurin 54 BCVA 54 univariate analysis 54 Peginterferon 54 risperidone 54 fluticasone furoate 54 microbiological eradication 54 tipranavir 54 ADHD RS 54 dexamethasone 54 Viread Emtriva SUSTIVA 54 nonobese 54 micafungin 54 HAMD 54 CK # plasma concentrations 54 aldosterone antagonists 54 BoNTA 54 df = 54 dosed orally 54 comparator PI r 54 plasma uric acid 54 #mg #mg #mg [003] 54 primary efficacy endpoints 54 concomitant AEDs